About: XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.85 (+6.02%)
XRTX NASDAQ XORTX Therapeutics Inc
XORTX Therapeutics Inc share price
XRTX price activity
Último preço
$ 1,850
Variação (24h)
0,11 USD (6,02%)
Volume
5.74M
Volume (média 4 sem.)
-
Abertura
$ 1,75
Variação do dia
$ 1,72 - $ 1,90
Fechamento anterior
$ 1,75
Último negócio
08 Oct, 8:29 pm GMT+0
Atrasado
08 Oct, 8:29 pm GMT+0
XRTX price performance
Atrasado
08 Oct, 8:29 pm GMT+0
quote.marketSignals